NASH Will Be Top of Mind at EASL, Nomura Says (ICPT)

Nomura Securities analyst M. Ian Somaiya weighed in on Intercept Pharmaceuticals (NASDAQ: ICPT) ahead of thee European Association for the Study of Liver Disease (EASL) meeting (April 22-26). The firm said Genfit data could benefit the company. The firm maintained a Buy rating and price target of $440.00.

"We believe NASH will also be top of mind at EASL following lackluster data from Genfit’s GFT505," Somaiya commented. "We believe Genfit’s analyst event (April 24) is unlikely to address lingering concerns about GFT505’s profile, allowing ICPT shares to continue to recover, with further upside when Phase III trial design is announced (2Q15)."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $271.77 yesterday.

You May Also Be Interested In

• Kotak Starts Dhoot Transmission (DHOOTTRA:IN) at Sell (4)
• Zscaler (ZS) PT Raised to $236 at RBC Capital
• Okta, Inc (OKTA) PT Raised to $235 at Truist Securities